Breast Cancer

This randomized multicenter pilot trial assesses feasibility of the THRIVE Wellness Program, a 6-week lifestyle intervention for young breast cancer survivors aged 40 years or younger.

Survey of safety-net breast cancer patients links stronger faith to greater trust in doctors, especially among Black and lower-income groups.

Explore how breast cancer stem cell plasticity, epigenetic reprogramming, and single-cell insights drive therapy resistance, revealing new targets to improve durable responses.

Explore how newer HER2 therapies and anthracycline-sparing regimens cut breast cancer heart damage, with monitoring and cardioprotective drugs.

Real-world study shows T-DXd benefits older metastatic breast cancer patients, but higher ILD risk and toxicity-driven discontinuation demand close monitoring, especially in octogenarians.

Does infusion timing matter in TNBC? Early-day pembrolizumab may boost pCR and cut recurrences, prompting new scheduling questions.

Clonal blood mutations common in breast cancer may sharply raise heart failure risk after anthracyclines, urging better screening and personalized cardio-oncology care.

Explore how ADCs reshape breast cancer care, with practical sequencing strategies across subtypes and guideline-based toxicity management for ILD, neutropenia, and GI effects.

Real-world data show most first-line mTNBC patients are immunotherapy-ineligible, use chemotherapy, and face poorer survival, underscoring major unmet treatment needs.

Phase 3 results support anbenitamab plus albumin-bound docetaxel as a new treatment option in HER2-positive breast cancer across disease stages.

T-DXd demonstrated a real-world overall response rate of 56.3%, median rwPFS of 7.4 months, and 12-month OS of 62% in patients with HER2-low metastatic breast cancer treated across US community oncology settings.

In a real-world cohort of 300 patients with HER2-low metastatic breast cancer, T-DXd demonstrated a safety profile consistent with DESTINY-Breast04 in community oncology settings, with ILD/pneumonitis in 10% and toxicity-related discontinuation in 15%.

Zovegalisib plus fulvestrant demonstrated an objective response rate of 38.7% and a median progression-free survival of 10.3 months in PIK3CA-mutant HR+/HER2– advanced breast cancer in the ReDiscover trial.

ctDNA-based next-generation sequencing in 236 patients with advanced breast cancer revealed frequent PIK3CA, TP53, and ESR1 mutations, highlighting key mechanisms of endocrine resistance with implications for targeted therapy selection.

Higher ACE counts were significantly associated with greater symptom burden during anti-estrogen therapy in patients with stage I to IV breast cancer in the Appalachian region of Tennessee.

Dato-DXd plus durvalumab demonstrated robust antitumor activity as first-line treatment for advanced/metastatic triple-negative breast cancer in the phase 1b/2 BEGONIA study, with manageable safety.

Although the results from persevERA were not statistically significant, they may support using oral SERDs for patients with ER+/HER2– breast cancer.

A phase 1/1b first-in-human study is evaluating the CNS-penetrant selective ERBB2 inhibitor CGT4255 across multiple tumor types, including HER2-positive breast cancer with brain metastases.

A dual-perspective survey of patients and physicians with metastatic breast cancer identified financial, logistical, and trust-related barriers to trial participation, with greater burden among racial and ethnic minorities.

Among US women aged 65 and older, foreign-born individuals showed higher self-reported breast cancer prevalence than US-born women, challenging assumptions from studies of younger populations.

Extended drug cessation appears feasible in exceptional responders with HER2+ de novo metastatic breast cancer, with significantly better survival compared with non-exceptional responders.

Data from the phase 3 SENOMAC trial showed that omitting completion ALND led to non-inferior 5-year OS and lower arm morbidity for patients with breast cancer.

Giredestrant improved invasive disease–free survival vs endocrine therapy for patients with ER+, HER2– early breast cancer in the phase 3 lidERA trial.

GLP-1 receptor agonist use was tied to reduced HR+/HER2− breast cancer incidence and improved overall survival in nondiabetic women with elevated BMI.

First-line sacitizumab govitecan plus pembrolizumab prolonged PFS2 PD-L1+ metastatic triple-negative breast cancer.